Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Dual-Targeting PSMA And FRα Drug Conjugate Advances to U.S. Trial for Prostate Cancer June 18, 2026
- Phase 1 RIALTO Trial: Radiotherapy for Metastatic Prostate Cancer With Incomplete Hormone Response June 18, 2026
- Decipher Genomic Classifier Identifies Patients Who Benefit from Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer June 18, 2026
- CRISPR Advances June 16, 2026

Google’s AI-Driven Breakthrough: The Future of Drug Discovery
/in Artificial Intelligence/by MaxWe can’t always win: LAVA-1207 Development Discontinued, Not Related to Safety Issues
/in Clinical Trial, Metastatic, Phase 1/by MaxUpdate on CLS-1025: Precision T Cell Engager Phase 1 Study Expected in Early 2025
/in Clinical Trial, Metastatic, Phase 1/by MaxUMass Scientists Develop Novel Bacteria-Based Cancer Therapy
/in Oncolytic, Preclinical Research/by MaxHarnessing PROTAC Technology: A Novel Approach to Targeting ERG in Prostate Cancer
/in Preclinical Research, PROTACs/by MaxVIR-5500: A Promising T-Cell Engager for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPreclinical: NRM-823, a Breakthrough T-Cell Engager Targeting Advanced Prostate Cancer
/in Immunotherapy, Preclinical Research/by MaxRPT04402 Reactivating PP2A: A Different Approach in Advanced Prostate Cancer Therapy
/in Preclinical Research/by Max